Novacyt
Novacyt S.A. develops and sells diagnostic products for cancer and infectious diseases. The last earnings update was 145 days ago. More info.
Add to Portfolio Compare Print
- Novacyt has significant price volatility in the past 3 months.
ALNOV Share Price and Events
7 Day Returns
1 Year Returns
ALNOV Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Novacyt (ALNOV) | 0.6% | -16.4% | -12.8% | -55.4% | -86.4% | -94.8% |
| FR Biotechs | 5% | -1.2% | -14.1% | -36.7% | -49.3% | -51.2% |
| FR Market | 3.5% | 5.5% | 3.6% | -1.6% | 27.6% | 25.6% |
1 Year Return vs Industry and Market
- ALNOV underperformed the Biotechs industry which returned -36.7% over the past year.
- ALNOV underperformed the Market in France which returned -1.6% over the past year.
ALNOV Value
Is Novacyt undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current
share
price of
Novacyt
to its discounted cash flow analysis.value.The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Below are the data sources, inputs and calculation used to determine the intrinsic value for Novacyt.
| Data Point | Source | Value |
|---|---|---|
| Valuation Model | 2 Stage Free Cash Flow to Equity | |
| Levered Free Cash Flow | Average of 1 Analyst Estimates (S&P Global) | See below |
| Discount Rate (Cost of Equity) | See below | 16.5% |
| Perpetual Growth Rate | 10-Year FR Government Bond Rate | 0.7% |
An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.
| Data Point | Calculation/ Source | Result |
|---|---|---|
| Risk-Free Rate | 10-Year FR Govt Bond Rate | 0.7% |
| Equity Risk Premium | S&P Global | 9.3% |
| Biotechs Unlevered Beta | Simply Wall St/ S&P Global | 1.25 |
| Re-levered Beta | = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.25 (1 + (1- 33%) (53.74%)) |
1.7 |
| Levered Beta | Levered Beta limited to 0.8 to 2.0 (practical range for a stable firm) |
1.7 |
| Discount Rate/ Cost of Equity |
= Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.73% + (1.7 * 9.27%) |
16.49% |
Discounted Cash Flow Calculation for ENXTPA:ALNOV using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for Novacyt is arrived at by discounting future cash flows to their present value using the 2 stage method. We use analyst's estimates of cash flows going forward 5 years for the 1st stage, the 2nd stage assumes the company grows at a stable rate into perpetuity.
| 2019 | 2020 | 2021 | 2022 | 2023 | |
| Levered FCF (EUR, Millions) | 1.70 | 2.02 | 2.39 | 2.79 | 3.24 |
| Source | Analyst x1 | Est @ 19%, capped from 39.83% | Est @ 18%, capped from 39.83% | Est @ 17%, capped from 39.83% | Est @ 16%, capped from 39.83% |
|
Present Value Discounted (@ 16.49%) |
1.46 | 1.49 | 1.51 | 1.52 | 1.51 |
| Present value of next 5 years cash flows | €7.49 |
| Calculation | Result | |
|---|---|---|
| Terminal Value |
= FCF2023
× (1 + g) ÷ (Discount Rate – g)
= €3.24 × (1 + 0.73%) ÷ (16.49% – 0.73%) |
€20.72 |
| Present Value of Terminal Value |
= Terminal Value ÷ (1 + r)5
= €20.72 ÷ (1 + 16.49%)5 |
€9.66 |
| Calculation | Result | |
|---|---|---|
| Total Equity Value |
= Present value of next 5 years cash flows +
Terminal Value
= €7.49 + €9.66 |
€17.15 |
| Equity Value per Share (EUR) |
= Total value / Shares Outstanding
= €17.15 / 37.56 |
€0.46 |
| Calculation | Result | |
|---|---|---|
| Value per share (EUR) | From above. | €0.46 |
| Current discount | Discount to share price of
€0.31
= -1 x (€0.31 - €0.46) / €0.46 |
31.7% |
Learn more about our DCF calculations in Simply Wall St’s analysis model .
Current Discount
Current Discount Checks
- Novacyt's share price is below the future cash flow value, and at a moderate discount (> 20%).
- Novacyt's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Novacyt's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Novacyt's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-06-30) in EUR | €-0.22 |
| ENXTPA:ALNOV Share Price ** | ENXTPA (2019-02-18) in EUR | €0.31 |
| Europe Biotechs Industry PE Ratio | Median Figure of 26 Publicly-Listed Biotechs Companies | 24.27x |
| France Market PE Ratio | Median Figure of 416 Publicly-Listed Companies | 15.13x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Novacyt.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = ENXTPA:ALNOV Share Price ÷ EPS (both in EUR) = 0.31 ÷ -0.22 |
-1.43x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Novacyt is loss making, we can't compare its value to the Europe Biotechs industry average.
- Novacyt is loss making, we can't compare the value of its earnings to the France market.
Price based on expected Growth
Does
Novacyt's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -1.43x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts |
Not available |
| Europe Biotechs Industry PEG Ratio | Median Figure of 21 Publicly-Listed Biotechs Companies | 1.45x |
| France Market PEG Ratio | Median Figure of 277 Publicly-Listed Companies | 1.3x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Novacyt, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Novacyt's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-06-30) in EUR | €1.00 |
| ENXTPA:ALNOV Share Price * | ENXTPA (2019-02-18) in EUR | €0.31 |
| France Biotechs Industry PB Ratio | Median Figure of 32 Publicly-Listed Biotechs Companies | 2.04x |
| France Market PB Ratio | Median Figure of 617 Publicly-Listed Companies | 1.49x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = ENXTPA:ALNOV Share Price ÷ Book Value per Share (both in EUR) = 0.31 ÷ 1.00 |
0.31x |
* Primary Listing of Novacyt.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Novacyt is good value based on assets compared to the FR Biotechs industry average.
Value checks
We assess Novacyt's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check) Novacyt has a total score of 2/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
ALNOV Future Performance
How is Novacyt expected to perform in the next 1 to 3 years based on estimates from 1 analyst?
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Unable to compare Novacyt's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
- Unable to compare Novacyt's earnings growth to the France market average as no estimate data is available.
- Novacyt's revenue growth is expected to exceed the France market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| ENXTPA:ALNOV Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts | 12.8% |
| France Biotechs Industry Earnings Growth Rate | Market Cap Weighted Average | 15.5% |
| France Biotechs Industry Revenue Growth Rate | Market Cap Weighted Average | 29.9% |
| France Market Earnings Growth Rate | Market Cap Weighted Average | 12.2% |
| France Market Revenue Growth Rate | Market Cap Weighted Average | 4.7% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (7 months ago) | See Below |
| Future Estimates | Average of up to 1 Analyst Estimates (S&P Global) | See Below |
| Date (Data in EUR Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2021-12-31 | 2 | |||
| 2020-12-31 | 2 | |||
| 2019-12-31 | 18 | 2 | 1 | |
| 2018-12-31 | 15 | 1 | 1 |
| Date (Data in EUR Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-06-30 | 15 | -4 | -6 |
| 2018-03-31 | 15 | -5 | -6 |
| 2017-12-31 | 15 | -5 | -5 |
| 2017-09-30 | 14 | -4 | -5 |
| 2017-06-30 | 13 | -3 | -4 |
| 2017-03-31 | 12 | -3 | -5 |
| 2016-12-31 | 11 | -3 | -6 |
| 2016-09-30 | 10 | -3 | -11 |
| 2016-06-30 | 9 | -4 | -16 |
| 2016-03-31 | 9 | -5 | -15 |
| 2015-12-31 | 9 | -5 | -14 |
| 2015-09-30 | 9 | -6 | -9 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (7 months ago) | See Below |
| Future Estimates | Average of up to 1 Analyst Estimates (S&P Global) | See Below |
All data from Novacyt Company Filings, last reported 7 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in EUR Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2021-12-31 | ||||
| 2020-12-31 | ||||
| 2019-12-31 | ||||
| 2018-12-31 |
| Date (Data in EUR Millions) | EPS * |
|---|---|
| 2018-06-30 | -0.22 |
| 2018-03-31 | -0.23 |
| 2017-12-31 | -0.24 |
| 2017-09-30 | -0.24 |
| 2017-06-30 | -0.25 |
| 2017-03-31 | -0.34 |
| 2016-12-31 | -0.47 |
| 2016-09-30 | -1.02 |
| 2016-06-30 | -1.77 |
| 2016-03-31 | -1.89 |
| 2015-12-31 | -2.05 |
| 2015-09-30 | -1.63 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if Novacyt will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Future performance checks
We assess Novacyt's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the France market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the France market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Novacyt has a total score of 1/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
ALNOV Past Performance
How has Novacyt performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Novacyt does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- Unable to compare Novacyt's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Novacyt's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
All data from Novacyt Company Filings, last reported 7 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in EUR Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-06-30 | 14.97 | -5.57 | 10.72 | 0.71 |
| 2018-03-31 | 14.96 | -5.51 | 10.47 | 0.76 |
| 2017-12-31 | 14.95 | -5.44 | 10.21 | 0.82 |
| 2017-09-30 | 14.05 | -4.67 | 9.96 | 0.79 |
| 2017-06-30 | 13.16 | -3.90 | 9.64 | 0.76 |
| 2017-03-31 | 12.12 | -4.80 | 9.13 | 0.78 |
| 2016-12-31 | 11.08 | -5.71 | 8.62 | 0.79 |
| 2016-09-30 | 10.10 | -10.70 | 8.01 | 0.73 |
| 2016-06-30 | 9.12 | -15.69 | 7.40 | 0.66 |
| 2016-03-31 | 9.01 | -14.80 | 7.16 | 0.63 |
| 2015-12-31 | 8.89 | -13.91 | 6.91 | 0.59 |
| 2015-09-30 | 8.80 | -9.50 | 6.72 | 0.71 |
| 2015-06-30 | 8.72 | -5.09 | 6.52 | 0.82 |
| 2015-03-31 | 6.62 | -4.50 | 4.98 | 0.64 |
| 2014-12-31 | 4.53 | -3.91 | 3.44 | 0.47 |
| 2014-09-30 | 2.76 | -2.48 | 2.73 | 0.67 |
| 2014-06-30 | 1.10 | -1.04 | 0.85 | |
| 2014-03-31 | 1.15 | -1.02 | 0.86 | |
| 2013-12-31 | 1.15 | -1.00 | 1.45 | 0.44 |
| 2013-09-30 | 1.19 | -0.81 | 0.78 | |
| 2013-06-30 | 1.17 | -0.63 | 0.70 | |
| 2013-03-31 | 1.14 | -0.59 | 0.61 | |
| 2012-12-31 | 1.10 | -0.56 | 0.53 | |
| 2012-09-30 | 1.02 | -0.67 | 0.54 | |
| 2012-06-30 | 0.94 | -0.79 | 0.54 | |
| 2012-03-31 | 0.93 | -0.74 | 0.56 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Novacyt has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if Novacyt has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Novacyt improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess Novacyt's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Novacyt has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
ALNOV Health
How is Novacyt's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Novacyt's finances.
The net worth of a company is the difference between its assets and liabilities.
- Novacyt is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Novacyt's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is covered by short term assets, assets are 1.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Novacyt Company Filings, last reported 7 months ago.
| Date (Data in EUR Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-06-30 | 23.02 | 6.30 | 2.16 |
| 2018-03-31 | 23.02 | 6.30 | 2.16 |
| 2017-12-31 | 24.91 | 3.89 | 4.36 |
| 2017-09-30 | 24.91 | 3.89 | 4.36 |
| 2017-06-30 | 19.82 | 8.05 | 2.59 |
| 2017-03-31 | 19.82 | 8.05 | 2.59 |
| 2016-12-31 | 17.77 | 6.26 | 2.87 |
| 2016-09-30 | 17.77 | 6.26 | 2.87 |
| 2016-06-30 | 16.67 | 5.76 | 1.77 |
| 2016-03-31 | 16.67 | 5.76 | 1.77 |
| 2015-12-31 | 10.52 | 3.37 | 1.69 |
| 2015-09-30 | 10.52 | 3.37 | 1.69 |
| 2015-06-30 | 19.88 | 1.38 | 1.33 |
| 2015-03-31 | 19.88 | 1.38 | 1.33 |
| 2014-12-31 | 20.27 | 1.03 | 2.34 |
| 2014-09-30 | 20.27 | 1.03 | 2.34 |
| 2014-06-30 | 20.75 | 1.15 | 1.57 |
| 2014-03-31 | 20.75 | 1.15 | 1.57 |
| 2013-12-31 | 2.25 | 0.21 | 1.00 |
| 2013-09-30 | 2.32 | 0.21 | 1.00 |
| 2013-06-30 | 2.15 | 0.73 | 1.31 |
| 2013-03-31 | 2.15 | 0.73 | 1.31 |
| 2012-12-31 | 1.64 | 1.12 | 1.67 |
| 2012-09-30 | 1.64 | 1.12 | 1.67 |
| 2012-06-30 | 0.03 | 1.30 | 0.50 |
| 2012-03-31 | 0.03 | 1.30 | 0.50 |
- Novacyt's level of debt (27.4%) compared to net worth is satisfactory (less than 40%).
- The level of debt compared to net worth has been reduced over the past 5 years (33.9% vs 27.4% today).
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- Novacyt has less than a year of cash runway based on current free cash flow.
- Novacyt has less than a year of cash runway if free cash flow continues to reduce at historical rates of -7.8% each year.
Financial health checks
We assess Novacyt's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Novacyt has a total score of 4/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
ALNOV Dividends
What is Novacyt's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
€2,000 of
Novacyt
shares you are expected to receive
€0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Novacyt's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Novacyt's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 1 Analyst Estimates (S&P Global) | See Below |
| Europe Biotechs Industry Average Dividend Yield | Market Cap Weighted Average of 10 Stocks | 0.9% |
| France Market Average Dividend Yield | Market Cap Weighted Average of 320 Stocks | 3.1% |
| France Minimum Threshold Dividend Yield | 10th Percentile | 1% |
| France Bottom 25% Dividend Yield | 25th Percentile | 1.7% |
| France Top 25% Dividend Yield | 75th Percentile | 4.4% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in €) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2021-12-31 | ||
| 2020-12-31 | ||
| 2019-12-31 | ||
| 2018-12-31 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Novacyt has not reported any payouts.
- Unable to verify if Novacyt's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Novacyt's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Novacyt afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Novacyt has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
ALNOV Management
CEO
| AGE | 55 |
| TENURE AS CEO | 5.1 years |
CEO Bio
Mr. Graham David Mullis has been the Chief Executive Officer of Novacyt Société Anonyme since 2014. Mr. Mullis served as the Chief Executive Officer of Lab21 Ltd. He served as the President of ClearLab International, a subsidiary of 1 800 Contacts Inc., from 2002 to November 20, 2006 and its Managing Director since 2002. He led the expansion of 1-800 CONTACTS overseas as well as leading Clearlab International. He has more than 10 years experience in leading medical device businesses and 8 years in the contact lens industry. He served as Managing Director of Biocompatibles Hydron and sold the business to CooperVision for $125 million. He launched the Proclear range of contact lenses at Biocompatibles, which is now a major product line for CooperVision , the fourth largest contact lens manufacturer in the world. He serves as a Director of Novacyt Société Anonyme. He served as a Director of Clearlab Pte Ltd. Mr. Mullis holds a Bachelors Degree in Biochemistry & Physiology from Southampton University and an MBA from Warwick Business School.
CEO Compensation
- Insufficient data for Graham to compare compensation growth.
- Insufficient data for Graham to establish whether their remuneration is reasonable compared to companies of similar size in France.
Management Team Tenure
Average tenure of the Novacyt management team in years:
- The average tenure for the Novacyt management team is less than 2 years, this suggests a new team.
Management Team
Graham Mullis
CEO & Director
55
5.1 yrs
Anthony Dyer
CFO, Company Secretary & Director
1.9 yrs
Mandy Cowling
Corporate & Investor Relations Manager
Wendy Karban
Group HR Manager
2 yrs
Phil Sefton
Managing Director of Lab21 Products Division
1.8 yrs
Ruth Powell
Managing Director of NOVAprep & Lab21 Services
Paul Eros
Managing Director of Primer Design
Gérald Ulrich
Chief Executive Officer of Business Development
Steve Gibson
Group Financial Controller
1.8 yrs
Ian Wilde
RA & QA Director
1.9 yrs
Board of Directors Tenure
Average tenure and age of the Novacyt board of directors in years:
- The average tenure for the Novacyt board of directors is less than 3 years, this suggests a new board.
Board of Directors
James Wakefield
Non-Executive Chairman of the Board
Graham Mullis
CEO & Director
55
Anthony Dyer
CFO, Company Secretary & Director
1.7 yrs
Andrew John Heath
Independent Senior Non-Executive Director
70
3.7 yrs
Juliet Thompson
Non-Executive Director
52
1.7 yrs
Jean-Pierre Crinelli
Non-Executive Director
€120K
David Gardner
Member of Scientific Committee
Marco Zonta
Member of Scientific Committee
Isabelle Cartier
Member of Scientific Committee
Geneviève Bourg-Heckly
Member of Scientific Committee
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (€) | Value (€) | |
|---|---|---|---|---|---|---|---|---|---|---|
Management checks
We assess Novacyt's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Novacyt has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
ALNOV News
Simply Wall St News
What Kind Of Investor Owns Most Of Novacyt S.A. (EPA:ALNOV)?
A look at the shareholders of Novacyt S.A. … Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … Companies that have been privatized tend to have low insider ownership.
Simply Wall St - – Full articleWhen Will Novacyt SA (EPA:ALNOV) Turn A Profit?
The €15m market-cap posted a loss in its most recent financial year of -€5m and a latest trailing-twelve-month loss of -€6m leading to an even wider gap between loss and breakeven. … Many investors are wondering the rate at which ALNOV will turn a profit, with the big question being “when will the company breakeven?” … In this article, I will touch on the expectations for ALNOV’s growth and when analysts expect the company to become profitable
Simply Wall St - – Full articleWho Really Owns Novacyt SA (EPA:ALNOV)?
I am going to take a deep dive into Novacyt SA’s (EPA:ALNOV) most recent ownership structure, not a frequent subject of discussion among individual investors. … The impact of a company's ownership structure affects both its short- and long-term performance. … Therefore, it is beneficial for us to examine ALNOV's ownership structure in more detail.
Simply Wall St - – Full articleNovacyt SA (EPA:ALNOV): Is Breakeven Near?
On 31 December 2017, the €26.98m market-cap posted a loss of -€5.44m for its most recent financial year. … Many investors are wondering the rate at which ALNOV will turn a profit, with the big question being “when will the company breakeven?” … I’ve put together a brief outline of industry analyst expectations for ALNOV, its year of breakeven and its implied growth rate
Simply Wall St - – Full articleHow Novacyt Société Anonyme (EPA:ALNOV) Can Impact Your Portfolio Volatility
A widely-used metric to measure a stock's market risk is beta, and the broad market index represents a beta value of one. … Based on this beta value, ALNOV appears to be a stock that an investor with a high-beta portfolio would look for to reduce risk exposure to the market. … Thus, we can expect ALNOV to be more stable in the face of market movements, relative to its peers of similar size but with a higher portion of fixed assets on their books.
Simply Wall St - – Full articleNovacyt Société Anonyme (EPA:ALNOV) And The Healthcare Industry Prospect For 2018
Novacyt Société Anonyme (ENXTPA:ALNOV), a €25.78M small-cap, is a healthcare company operating in an industry, which has experienced tailwinds from issues such as higher demand driven by an aging population and the increasing prevalence of diseases and comorbidities. … In this article, I’ll take you through the sector growth expectations, as well as evaluate whether Novacyt Société Anonyme is lagging or leading its competitors in the industry. … View our latest analysis for Novacyt Société Anonyme What’s the catalyst for Novacyt Société Anonyme's sector growth?
Simply Wall St - – Full articleWhere Novacyt Société Anonyme (EPA:ALNOV) Stands In Earnings Growth Against Its Industry
Assessing Novacyt Société Anonyme's (ENXTPA:ALNOV) performance as a company requires looking at more than just a years' earnings data. … Below, I will run you through a simple sense check to build perspective on how Novacyt Société Anonyme is doing by comparing its most recent earnings with its historical trend, in addition to the performance of its biotechs industry peers. … Check out our latest analysis for Novacyt Société Anonyme Were ALNOV's earnings stronger than its past performances and the industry?
Simply Wall St - – Full articleShould You Be Concerned About Novacyt Société Anonyme's (EPA:ALNOV) Investors?
Today, I will be analyzing Novacyt Société Anonyme’s (ENXTPA:ALNOV) recent ownership structure, an important but not-so-popular subject among individual investors. … Private Company Ownership Another important group of owners for potential investors in ALNOV are private companies that hold a stake of 3.54% in ALNOV. … Thus, investors not need worry too much about the consequences of these holdings.Next Steps: With a low level of institutional ownership, investors in ALNOV need not worry about non-fundamental factors such as ownership structure causing large impact on stock prices.
Simply Wall St - – Full articleNovacyt Société Anonyme (EPA:ALNOV): Is Breakeven Near?
Many investors are wondering the rate at which ALNOV will turn a profit, with the big question being “when will the company breakeven?” In this article, I will touch on the expectations for ALNOV’s growth and when analysts expect the company to become profitable. … Check out our latest analysis for Novacyt Société Anonyme According to the industry analysts covering ALNOV, breakeven is near. … Working backwards from analyst estimates, it turns out that they expect the company to grow 69.71% year-on-year, on average, which is rather optimistic!
Simply Wall St - – Full articleALNOV Company Info
Map
Description
Novacyt S.A. develops and sells diagnostic products for cancer and infectious diseases. The company’s diagnostic products are used in liquid based cytology, oncology, microbiology, haematology, and serology testing. It offers NovaPrep, a liquid based cytology solution that is utilized in the diagnosis of cervical cancer; and clinical laboratory testing services to clinicians, healthcare providers, and patients. The company also develops, manufactures, and distributes diagnostic products for clinical and food laboratories; and manufactures and markets vitro diagnostic tests, as well as diagnostic reagents, test kits, and blood grouping reagents. It serves hospitals and large corporates. The company was founded in 2006 and is based in Vélizy-Villacoublay, France.
Details
| Name: | Novacyt S.A. |
| ALNOV | |
| Exchange: | ENXTPA |
| Founded: | 2006 |
| €11,720,230 | |
| 37,564,842 | |
| Website: | http://www.novacyt.com |
| Address: |
Novacyt S.A. 13 Avenue Morane Saulnier, Vélizy-Villacoublay, Ile-de-France, 78140, France |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| ENXTPA | ALNOV | Common Stock | Euronext Paris | FR | EUR | 12. Oct 2012 | |
| BST | NYZ | Common Stock | Boerse-Stuttgart | DE | EUR | 12. Oct 2012 | |
| AIM | NCYT | Common Stock | London Stock Exchange AIM Market | GB | GBP | 12. Oct 2012 |
Number of employees
Current staff
Industry
| Biotechnology | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/02/18 22:52 |
| End of day share price update: | 2019/02/18 00:00 |
| Last estimates confirmation: | 2019/01/22 |
| Last earnings filing: | 2018/09/26 |
| Last earnings reported: | 2018/06/30 |
| Last annual earnings reported: | 2017/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
